Trial Profile
A Safety and Pilot Activity Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2014
Price :
$35
*
At a glance
- Drugs Ecopipam (Primary)
- Indications Lesch-Nyhan syndrome
- Focus Adverse reactions
- Sponsors Psyadon Pharmaceuticals
- 29 Mar 2014 New trial record